Opinions: MDG Progress; Drug Patents; Aid For Scientific Research; Avoiding Food Crises; Hunger In India; U.S. Commitments To PEPFAR, Global Fund

MDGs Are Less About Timeline, More About Identifiable Progress “Between the catastrophes of the Haiti earthquake and the Pakistan floods, there was actually some good news this spring on the global health front, which offers hope that the United Nations’ ambitious Millennium Development Goals might [...]

Also In Global Health News: GM Mosquitoes; Iodine Deficiency In Nepal; South African Health Workers Strike; Novartis To Build Vaccine Plant In Brazil;

Malaysia Considers GM Mosquito Release To Control Dengue Fever Malaysia is still “considering releasing” up to 3,000 mosquitoes that are genetically modified to “combat dengue fever, in a landmark field trial that has come in for criticism from environmentalists,” Agence France-Presse reports…

New Centre Will Develop New Drugs For Diseases

New treatments for some of our most common diseases and conditions could be on the horizon with the launch of a new drug discovery venture in Aberdeen. The University of Aberdeen will next month officially open its new Kosterlitz Centre for Therapeutics which will take the findings of researchers and clinicians and support [...]

pSivida announces FDA Priority Review status for Iluvien NDA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment [...]

Stromedix’s STX-100 receives orphan drug status from FDA for treatment of IPF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive [...]

Halozyme identifies strategy to reintroduce HYLENEX

Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover’s list of the “Top 10 Most Interesting Neuroscience Projects to Watch.”

TearLab and AMO Canada enter cooperative marketing agreement

TearLab Corporation today announced that it has entered into a cooperative marketing agreement with Abbott Medical Optics Inc.’s subsidiary, AMO Canada Company. Under the agreement, AMO Canada’s sales force will directly sell the TearLab™ Osmolarity System in Canada while TearLab will help promote AMO Canada’s products for the relief of dry eye symptoms, including Blink® [...]

Nutritional recommendations for management of sarcopenia published

Nutritional recommendations for the management of sarcopenia — also described as age-related muscle and functional loss — were published this past week in the clinical publication, Journal of American Medical Directors Association.

EDIMS licenses First DataBank’s National Drug Data File Plus database

First DataBank, a leading provider of drug databases that help drive patient safety, and EDIMS, a leading provider of interoperable emergency department (ED) information management systems, today announced they have licensed First DataBank’s National Drug Data File (NDDF) Plus™ database to offer hospitals greater choice in trusted third-party drug database information to use and integrate [...]